An American medical journal will this week publish a major study that GlaxoSmithKline says will back up its fierce defence of Avandia, its diabetes treatment whose safety has been called into question.
The results of the GSK-commissioned study of 30,000 diabetes patients in a real-world setting, to be published as soon as tomorrow, is expected to show that Avandia has a safety profile similar to rival treatments. The FTSE 100 drug giant hopes that will mean a reprieve after a horrid two weeks, in which it has seen 11.8 per cent of its market value, or £9.8bn, wiped away.
The identity of the American publication was being closely guarded this weekend because of fears that it would be inundated with calls if it was revealed.
More
No comments:
Post a Comment